Genmab A/S (GMAB)

NMS – Real vaqt narxi. Valyuta: USD

27.09

+0.91 (3.48%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.

07.05.2026

Genmab Announces Financial Results for the First Quarter of 2026

May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025 , to $896 million FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line plus relapsed/refractory DLBCL Remained focused on disciplined investment in our late-stage portfolio, EPKINLY ® (epcoritamab), Rina-S ® , and petosemtamab, including launch readiness “We made tangible progress in the first quarter as we continue to integrate Merus™ and advance our late-stage portfolio - EPKINLY, Rina-S and petosemtamab. Across the business, our focus remained on disciplined execution, progressing these programs toward key readouts and preparing for potential launches to have an impact on more patients,” said Jan van de Winkel, Ph.D.

17.04.2026

Genmab A/S Share Capital Reduction

Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital with nominally DKK 1,900,000 by cancellation of 1,900,000 of the Company's holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority.

14.04.2026

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of April 13, 2026, Orbis Investment Management Limited through shares controlled the voting rights to 3,114,318 shares in Genmab A/S, which amounts to 4.85% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.

14.04.2026

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 3,964 million in the first quarter of 2026. Net trade sales were USD 2,208 million in the U.S. and USD 1,756 million in the rest of the world.

13.04.2026

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in combination with bevacizumab in patients with advanced ovarian cancer, showed a safety profile consistent with the known safety profiles of Rina-S and bevacizumab. These data are from the combination therapy cohort D2 of the.

13.04.2026

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ® ) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The ongoing Phase 3 RAINFOL-04 trial will further evaluate the combination in patients with recurrent platinum-sensitive ovarian cancer (PSOC) Genmab A/S (Nasdaq: GMAB ) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in combination with bevacizumab in patients with advanced ovarian cancer, showed a safety profile consistent with the known safety profiles of Rina-S and bevacizumab. These data are from the combination therapy cohort D2 of the multi-part Phase 1/2 RAINFOL™-01 study and were presented during an oral session at the 2026 Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO) in San Juan, Puerto Rico.

Videolar

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

01.08.2025

Negative

President Trump demands drugmakers slash prices within 60 days

Press-relizlar

12.05.2026

Genmab A/S (GMAB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Genmab A/S (GMAB)

Capital Increase in Genmab as a Result of Employee Warrant Exercise